PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.65%
Cash & equivalents declining -7.65% while AGEN's grows 14.91%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-7.65%
Below half of AGEN's 14.91%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of AGEN's 84.22%. David Dodd sees a leaner approach to short-term items.
-5.46%
Below half of AGEN's 10.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.35%
Below half AGEN's -2.80%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Non-Current Assets Growth compared to AGEN's zero value, indicating worse performance.
2.60%
Below half of AGEN's -1.98%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Below half of AGEN's 4.54%. Michael Burry sees a potential red flag for stagnation or capital shortage.
41.04%
Above 1.5x AGEN's 22.23%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.09%
Above 1.5x AGEN's 16.96%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.41%
Above 1.5x AGEN's 18.74%. Michael Burry sees a potential leverage warning sign.
4.74%
Above 1.5x AGEN's 1.39%. Michael Burry suspects heavy new equity expansion or dilution.
-3.50%
0.75-0.9x AGEN's -4.23%. Bill Ackman questions if competitor reinvests profits more robustly.
-4.99%
Less than half of AGEN's 4.74%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-23.90%
0.5-0.75x AGEN's -32.25%. Martin Whitman is wary of lagging equity growth vs. competitor.
-5.18%
Below half AGEN's 4.54%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.42%
Less than half of AGEN's -20.40%. David Dodd sees better deleveraging or stronger cash buildup than competitor.